↓ Skip to main content

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial

Overview of attention for article published in BMC Cancer, August 2017
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
159 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial
Published in
BMC Cancer, August 2017
DOI 10.1186/s12885-017-3538-4
Pubmed ID
Authors

J. De Smedt, S. Van Kelst, V. Boecxstaens, M. Stas, K. Bogaerts, D. Vanderschueren, C. Aura, K. Vandenberghe, D. Lambrechts, P. Wolter, O. Bechter, A. Nikkels, T. Strobbe, G. Emri, V. Marasigan, M. Garmyn

Abstract

Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D supplementation, in the follow-up period after diagnosis and surgical resection of the primary tumor, has a protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates with vitamin D levels in serum and Vitamin D Receptor immunoreactivity in the primary tumor. This study is a multicenter randomized double blind placebo- controlled phase III trial. Patients between the age of 18 and 80 years diagnosed and treated surgically for a melanoma stage IB-III are eligible for randomization in a 1:1 ratio to active treatment or placebo. The study drug is taken each month and consists of either 100,000 International Unit cholecalciferol or arachidis oleum raffinatum used as a placebo. The primary endpoint is relapse free survival. The secondary endpoints are 25 hydroxyvitamin D3 serum levels at diagnosis and at 6 month intervals, melanoma subtype, melanoma site and stage of melanoma at diagnosis according to the 2009 American Joint Committee on Cancer melanoma staging and classification. At randomization a bloodsample is taken for DNA analysis. The study is approved by the local Ethics Committees. If we can confirm our hypothesis that vitamin D supplementation after removal of the tumor has a protective effect on relapse of cutaneous malignant melanoma we may reduce the burden of CMM at several levels. Patients, diagnosed with melanoma may have a better clinical outcome and improved quality of life. There will be a decrease in health care costs related to treatment of metastatic disease and there will be a decrease in loss of professional years, which will markedly reduce the economic burden of the disease. Clinical Trial.gov, NCT01748448 , 05/12/2012.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 159 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 29 18%
Student > Master 20 13%
Researcher 14 9%
Other 11 7%
Student > Postgraduate 10 6%
Other 25 16%
Unknown 50 31%
Readers by discipline Count As %
Medicine and Dentistry 49 31%
Nursing and Health Professions 23 14%
Biochemistry, Genetics and Molecular Biology 7 4%
Agricultural and Biological Sciences 4 3%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 16 10%
Unknown 56 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2020.
All research outputs
#18,569,430
of 22,999,744 outputs
Outputs from BMC Cancer
#5,461
of 8,356 outputs
Outputs of similar age
#243,354
of 317,355 outputs
Outputs of similar age from BMC Cancer
#87
of 127 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,356 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,355 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.